ライフサイエンスコーパス: dysphoria

1 ing the sensitivity to stressful stimuli and dysphoria.

2 ased signaling may produce analgesia without dysphoria.

3 depressive-like states such as anhedonia and dysphoria.

4 rbance and co-occurring anxiety disorders or dysphoria.

5 se without a history of anxiety disorders or dysphoria.

6 high rates of anxiety disorders and chronic dysphoria.

7 d is consistent with a link between CREB and dysphoria.

8 2 because of vernacular changes referring to dysphoria.

9 s anhedonia, craving, fatigue, insomnia, and dysphoria.

10 ren and may be prodromal markers of risk for dysphoria.

11 More than 1 in 4 patients had moderate dysphoria.

12 rapeutic options for women with premenstrual dysphoria.

13 A history of major depressive episode, dysphoria (2 weeks of sadness), and psychotropic medicat

14 ects of diagnosis and treatment condition on dysphoria after quitting smoking and the effects of dysp

15 Dysphoria alone was not reliably related to pain reports

16 These data suggest that a history of dysphoria and a major depressive episode increase the ri

17 be improved by using multiple questions for dysphoria and a simpler mode of inquiry.

18 profile suggests that it will be without the dysphoria and other adverse effects promoted by arrestin

19 pression in patients with CVD improves their dysphoria and other signs and symptoms of depression, im

20 ole of ovarian steroids in both premenstrual dysphoria and perimenopausal depression has led to the s

21 he case of kappa-opioid receptor (kappa-OR)--dysphoria and psychotomimesis.

22 rs an approach to controlling stress-induced dysphoria and relapse.

23 0488, a kappa-opioid agonist known to induce dysphoria and stress-like effects in rodents.

24 or without surgery, to improve their gender dysphoria and to better align their physical and psychol

25 d, implicates dynorphin as a key mediator of dysphoria, and emphasizes kappa-receptor antagonists as

26 ed by some KOR agonists, including sedation, dysphoria, and hallucinations, have limited their clinic

27 er scores for items related to anger, worry, dysphoria, and irritability.

28 icolimbic system; the ensuing kappa-mediated dysphoria appears to contribute to addiction and withdra

29 experience reward (anhedonia) and aversion (dysphoria) are in high demand because many psychiatric c

30 r than placebo for treatment of premenstrual dysphoria as reflected by symptomatic improvement and ch

31 Interestingly, KOR-mediated dysphoria, assessed in rodents as aversion, has recently

32 Dysphoria associated with KOR activation limits the ther

33 ain the rapid alleviation of the anxiety and dysphoria associated with late luteal phase dysphoria di

34 ld contribute to alleviating the anxiety and dysphoria associated with the symptomatology of major un

35 with analgesia being G protein-mediated and dysphoria being mediated through betaarrestin2 recruitme

36 ot with dysphoria; pattern 2 correlated with dysphoria but not with the cognitive measures.

37 tinue the study, and have increased rates of dysphoria, depressive symptoms, and extrapyramidal sympt

38 Gender dysphoria describes the psychological distress caused by

39 dysphoria associated with late luteal phase dysphoria disorder and major unipolar depression by thes

40 sts produce other adverse effects, including dysphoria, diuresis, and constipation.

41 Transgender women experience lifelong gender dysphoria due to a gender assignment at birth that is in

42 fective symptoms reflecting areas of chronic dysphoria (e.g., anger and loneliness/emptiness) and int

43 h mania, and the bimodal distribution of the dysphoria factor is consistent with the possibility that

44 hypofunction and dysthymic disorder include dysphoria, fatigue, and low libido.

45 and loss (ie, emotional numbing, depression/dysphoria, generalized anxiety) symptomatology.

46 inverse of measures of pervasive anxiety and dysphoria (i.e., negative affectivity).

47 olecular mechanisms mediating stress-induced dysphoria in humans and conditioned place aversion in ro

48 The first and strongest factor represented dysphoria in mania, with strong positive loadings for de

49 different forms of stress presumed to evoke dysphoria in mice, we found that repeated forced swim an

50 ms responsible for cognitive dysfunction and dysphoria in nondemented patients with Parkinson's disea

51 ductive age have some physical discomfort or dysphoria in the weeks before menstruation.

52 le in the assessment and treatment of gender dysphoria in transgender individuals.

53 eported more pain than those without current dysphoria, irrespective of whether they had a history of

54 Extreme dysphoria is common in borderline personality disorder (

55 Understanding how KOR activation produces dysphoria is key to the development of better analgesics

56 oid receptor (KOR) system leads to aversive, dysphoria-like behavior.

57 tors (KORs) in monoamine circuits results in dysphoria-like behaviors and stress-induced reinstatemen

58 ng in different stress responses: analgesia, dysphoria-like behaviors, anxiety-like responses, and in

59 roadly consistent with Simms and colleagues' Dysphoria Model of PTSD symptoms) which provided a bette

60 ed by neuroendocrine dysregulation, fatigue, dysphoria, myalgia, and impaired mental and physical per

61 e disorders, anhedonia (lack of pleasure) or dysphoria (negative affect) can result from breakdowns o

62 with lifetime anxiety disorders and lifetime dysphoria (odds ratio=3.82, 95% CI=1.56-9.38, and odds r

63 ia after quitting smoking and the effects of dysphoria on abstinence.

64 Among individuals with no history of dysphoria, only lithium use was significantly associated

65 egulation of reward processing manifested in dysphoria, or affective withdrawal.

66 patial and mnemonic functioning but not with dysphoria; pattern 2 correlated with dysphoria but not w

67 itoral enlargement, and reductions in gender dysphoria, perceived stress, anxiety, and depression.

68 aused by treatments that cause anhedonia and dysphoria (prodepressive effects) in rats and humans (e.

69 ith general depression (R = -.523, P = .01), dysphoria (R = -.455, P = .05), and lassitude (R = -.449

70 The dependence of both negative (dysphoria-related) and positive (antidepressant-induced)

71 atment, indicating that these behaviors were dysphoria-related.

72 ssive symptoms at the time of the interview (dysphoria) reported more pain than those without current

73 tility, narcissism, emotional dysregulation, dysphoria, schizoid orientation, obsessionality, thought

74 Some idioms for dysphoria seemed to work better than others.

75 epressed women met criteria for premenstrual dysphoria (symptom cyclicity and at least moderate sever

76 ms; this association was most pronounced for dysphoria symptoms (r = -0.45; 95% CI, -0.10 to -0.70).

77 ing and hyperarousal symptoms, and loss (ie, dysphoria) symptoms, such as emotional numbing and depre

78 typic expression of trauma-related loss (ie, dysphoria) symptoms.

79 ith episodes of binge cocaine use and in the dysphoria that follows abrupt cocaine withdrawal.

80 Compared with respondents with no history of dysphoria, the odds ratio for MI associated with a histo

81 : one defined by emotional dysregulation and dysphoria, the other by histrionic characteristics.

82 n-releasing factor (CRF) in the induction of dysphoria, the potentiation of drug seeking, and stress-

83 bic pathway has been proposed to mediate the dysphoria underlying this response, we tested dopamine-d

84 ds ratio for MI associated with a history of dysphoria was 2.07 (95% CI, 1.16 to 3.71), and the odds

85 s-related symptom cyclicity nor premenstrual dysphoria was an invariant accompaniment of perimenopaus

86 In the entire group, dysphoria was found in 33%, delusional ideation in 39%,

87 Additionally, the rate of premenstrual dysphoria was not predicted by initial self-reports.

88 s-related symptom cyclicity and premenstrual dysphoria was observed in perimenopausal depressed women

89 c correlates of responses to questions about dysphoria were examined.

90 al syndrome and postpartum or postmenopausal dysphoria, when increased emotional lability and BDZ ins

91 ve emotional symptoms, such as anhedonia and dysphoria, which may be due in part, to dysfunction of t